Simple Summary Anti-PD-1/PD-L1 and anti-CTLA-4-based immune checkpoint blockade
(ICB) immunotherapy have recently emerged as a breakthrough in human cancer treatment …

The ability of physicians to effectively treat and cure cancer is directly dependent on their
ability to detect cancers at their earliest stages. Proteomic analyses of early-stage cancers …

Ovarian cancer is the leading cause of gynecological malignancy–related deaths, due to its
widespread intraperitoneal metastases and acquired chemoresistance. Mesothelial cells are …

OBJECTIVES.: The CA125 tumor marker is used to help predict the presence of ovarian
cancer in patients with an adnexal mass. Because elevated CA125 levels occur in many …

Abstract Background: Updated National Academy of Clinical Biochemistry (NACB)
Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been …

Trophoblast research over the past decades has underlined the striking similarities between
the proliferative, migratory and invasive properties of placental cells and those of cancer …

Background Acquired epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)
resistance limits the long-term clinical efficacy of tyrosine kinase-targeting drugs. Although …

Ovarian cancer is characterize by few early symptoms, presentation at an advanced stage,
and poor survival. As a result, it is the most frequent cause of death from gynecological …

Disease biomarkers are used widely in medicine. But very few biomarkers are useful for
cancer diagnosis and monitoring. Over the past 15 years, major investments have been …

A variety of biomarkers have been developed to monitor growth of ovarian cancer and to
detect disease at an early interval. CA125 (MUC16) has provided a useful serum tumor …